(Approval lapsed) MOXYPEN FORTE Amoxicillin as trihydrate 500mg Capsules (TEVA)
Section 19A approved medicine
(Approval lapsed) MOXYPEN FORTE Amoxicillin as trihydrate 500mg Capsules (TEVA)
Section 19A approval holder
Pro Pharmaceuticals Group Pty Ltd ABN 20 605 457 430
Phone
1300 077 674
Approved until
Status
Expired
Medicines in short supply/unavailable
ALPHAMOX 500 amoxicillin 500mg (as trihydrate) capsule blister pack - ARTG 17679
Indication(s)
For the treatment of the following infections due to susceptible strains of sensitive organisms.
Note: Therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. However, in emergency cases where the causative organism has not been identified, therapy with amoxicillin may be useful. Clinical judgement will decide whether combination with another antibiotic would provide a sufficiently broad spectrum of activity pending sensitivity test results.
- Skin and Skin Structure- Staphylococcus, non-penicillinase producing; Streptococcus; E. coli.
- Respiratory (Acute and Chronic)- H. influenzae; Streptococcus; Strep. pneumoniae; Staphylococcus, non-penicillinase producing; E. coli
- Genitourinary Tract (Complicated and Uncomplicated, Acute and Chronic)- E. coli, P. mirabilis and S. faecalis.
- Gonorrhoea- N. gonorrhoeae (non-penicillinase producing).
- Prophylaxis of Endocarditis- Amoxicillin may be used for the prophylaxis of bacterial endocarditis in individuals at particular risk, such as those with a prosthetic heart valve or those who have previously had endocarditis.